ER2001 / ExoRNA Biosci - LARVOL DELTA

The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease. (clinicaltrials.gov) - P1 | N=8 | Completed | Sponsor: ExoRNA Bioscience | Active, not recruiting ➔ Completed

Trial completion • CNS Disorders • Genetic Disorders • Huntington's Disease • Movement Disorders

A Randomized, Blinded, Placebo-Controlled Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease (ChiCTR) - P1 | N=27 | Completed | Sponsor: The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital,Sun Yat-sen University

New P1 trial • CNS Disorders • Huntington's Disease • Movement Disorders

The Safety and Tolerability Study With ER2001 Intravenous Injection Repetitive Treatment in Adults With Early Manifest Huntington's Disease. (clinicaltrials.gov) - P1 | N=9 | Active, not recruiting | Sponsor: ExoRNA Bioscience

New P1 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

A Phase I Clinical Study of ER2001 Injection for the Treatment of Early Manifest Huntington's Disease. (clinicaltrials.gov) - P1/2 | N=27 | Active, not recruiting | Sponsor: ExoRNA Bioscience

New P1/2 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease (clinicaltrials.gov) - P1 | N=10 | Completed | Sponsor: ExoRNA Bioscience | Recruiting ➔ Completed | N=15 ➔ 10 | Trial completion date: Dec 2024 ➔ Sep 2025 | Trial primary completion date: Oct 2024 ➔ Jan 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Genetic Disorders • Huntington's Disease • Movement Disorders

First-in-Man Clinical Pilot Study Showing the Safety and Tolerability of Intravenous Injection of ER2001 (a Self-Assembled HTT-Specific siRNA) in Patients with Early Manifest HD (HSG 2024) - "Intravenous injection of ER2001 is safe and feasible in patients with early manifest HD, thus warranting further evaluation in randomized clinical trials."

Clinical